Search PubMed⌕ Search

Biomedical subjects

B Taillan

Publications and source records attributed to B Taillan.

At least 217 records · Page 12Linked to original sources
PubMedDate not supplied

[Heparin-like anticoagulant in small cell bronchial carcinoma].

Acquired circulating heparin-like anticoagulants may have different causes, the most frequent being plasmocyte proliferation. The authors report an exceptional case of association between an heparin-like inhibitor and a small-cell anaplastic lung carcinoma, and they review the pathogenesis, laboratory diagnostic methods and treatment of the anticoagulant.

Carcinoma, Small Cell↗
PubMedDate not supplied

[Jaundice caused by rifampicin: 3 cases].

Three cases are reported of cholestatic hepatitis occurring during treatment with rifampicin for staphylococcal septicemia (2) and tuberculosis (1). There was no previous history of hepatic affection. The administration of rifampicin caused cholestasis alone. No immunoallergic phenomenon has been shown.

Aged↗
PubMedDate not supplied

[Systemic complications of beta-blocking eyedrops. Apropos of 6 cases].

Six cases of systemic reactions to topical treatment with beta-blocking eyedrops are reported, bradycardia and faintness due to an overdosage of ophthalmic timolol; decompensated heart failure one month after the prescription of carteolol eyedrops: bronchospasm after two weeks of treatment with metipranolol eyedrops; crippling Raynaud's phenomenon of otherwise unknown origin, which had begun with timolol eyedrops, continued with carteolol eyedrops and regressed after discontinuation of ophthalmic beta-blockers; aggravation of an anaphylactoid shock in a patient treated with ophthalmic timolol, and myocardial infarction possibly due to the abrupt withdrawal of timolol eyedrops. It cannot be overstressed that the rules governing the prescription of oral beta-blockers also apply to ophthalmic preparations of these drugs: respect of contra-indications, strict adherence to the dosage recommended, gradual drug withdrawal and regular supervision. Only controlled studies and long-term follow-up will be able to demonstrate differences in safety between the five beta-blockers commercialized as eyedrops in this country.

Adrenergic beta-Antagonists↗